-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[ Star Enterprise of Chemical Machinery Equipment Network ] Scientific research instruments are the "eyes" of scientists and the cornerstone of scientific research and technological innovation
.
Chemical Machinery Equipment Net Star Enterprise Chemical Machinery Equipment.
In recent years, the global instrument industry has flourished and maintained a good momentum.
Now that 2021 has ended, the financial reports of major listed instrument companies have also been released.
The editor of Chemical Instrument Network has specially compiled the public financial report data of 12 instrument companies (foreign), For industry reference
.
Now that 2021 has ended, the financial reports of major listed instrument companies have also been released.
The editor of Chemical Instrument Network has specially compiled the public financial report data of 12 instrument companies (foreign), For industry reference
.
Performance of 12 foreign listed instrument companies in 2021
According to the public financial report data, the 2021 total performance of the 12 companies summarized this time has increased to varying degrees
.
In terms of overall performance, Thermo Fisher's performance increased by US$6.
993 billion from the previous year to US$39.
211 billion, ranking first in total performance; Danaher's performance increased by US$7.
169 billion from the previous year to US$29.
453 billion, The overall performance ranks second
.
.
In terms of overall performance, Thermo Fisher's performance increased by US$6.
993 billion from the previous year to US$39.
211 billion, ranking first in total performance; Danaher's performance increased by US$7.
169 billion from the previous year to US$29.
453 billion, The overall performance ranks second
.
In terms of performance gains, 11 of the 12 companies have increased by double digits.
Danaher, PerkinElmer, and Illumina have all increased by more than 30%, and Illumina has reached 40%
.
Danaher, PerkinElmer, and Illumina have all increased by more than 30%, and Illumina has reached 40%
.
Judging from the company's performance forecast for 2022 that can be counted in the financial report, most companies have a positive attitude towards the performance in 2022
.
But among them, PerkinElmer's performance expectations for 2022 are down 11.
2%-16.
7% from the total performance in 2021, and it predicts that revenue related to COVID-19 in 2022 will be at least $400 million, while Perkin's 2021 revenue Elmer's COVID-19-related revenue totaled approximately $1.
6 billion
.
.
But among them, PerkinElmer's performance expectations for 2022 are down 11.
2%-16.
7% from the total performance in 2021, and it predicts that revenue related to COVID-19 in 2022 will be at least $400 million, while Perkin's 2021 revenue Elmer's COVID-19-related revenue totaled approximately $1.
6 billion
.
Judging from the financial data of various departments disclosed in the financial report, the life sciences and diagnostics businesses are still strong growth points
.
Representative companies such as Thermo Fisher Scientific and Danaher's life science divisions saw their performances rise by 28.
5% and 44.
4%; Danaher and Qiagen's medical diagnostics divisions rose by 33% and 27%, respectively
.
.
Representative companies such as Thermo Fisher Scientific and Danaher's life science divisions saw their performances rise by 28.
5% and 44.
4%; Danaher and Qiagen's medical diagnostics divisions rose by 33% and 27%, respectively
.
Affected by the new crown epidemic, companies have deployed and developed related products one after another, which has an obvious role in boosting business growth
.
Notably, some companies, such as PerkinElmer, whose COVID-19-related product revenue fell by more than $200 million compared to 2020, have projected 2022 COVID-19-related product revenue of "no less than $400 million.
" U.
S.
dollar,” relatively conservative
.
.
Notably, some companies, such as PerkinElmer, whose COVID-19-related product revenue fell by more than $200 million compared to 2020, have projected 2022 COVID-19-related product revenue of "no less than $400 million.
" U.
S.
dollar,” relatively conservative
.
In 2021, each company's emphasis on R&D in corporate operations is also reflected in the disclosed financial reports.
The total R&D invested by Danaher in 2021 will be 1.
742 billion yuan, accounting for 5.
9% of the company's total performance in 2021, an increase of 29% over the previous year.
% (the annual performance increased by more than 7.
1 billion US dollars); the total amount of R&D invested by lumina was 1.
19 billion, accounting for 26.
3% of the total revenue, an increase of 74.
5% over the previous year (a performance increase of 40%)
.
The total R&D invested by Danaher in 2021 will be 1.
742 billion yuan, accounting for 5.
9% of the company's total performance in 2021, an increase of 29% over the previous year.
% (the annual performance increased by more than 7.
1 billion US dollars); the total amount of R&D invested by lumina was 1.
19 billion, accounting for 26.
3% of the total revenue, an increase of 74.
5% over the previous year (a performance increase of 40%)
.
Note: The "2022 Outlook" of some companies in the chart is calculated based on the expected growth in the financial reports announced by each company
.
.
Attachment: Excerpts from the financial reports of 12 instrument companies
Thermo Fisher
For all of 2021, Thermo's revenue rose 22% to $39.
21 billion, compared to $32.
22 billion in 2020
.
The revenue generated by COVID-19-related businesses totaled $9.
23 billion
.
The underlying business also performed well, achieving 14% growth
.
Organic revenue was up 17%, acquisition revenue was up 3% and currency translation revenue was up 2%
.
21 billion, compared to $32.
22 billion in 2020
.
The revenue generated by COVID-19-related businesses totaled $9.
23 billion
.
The underlying business also performed well, achieving 14% growth
.
Organic revenue was up 17%, acquisition revenue was up 3% and currency translation revenue was up 2%
.
Among the four divisions, the revenue of the life science solutions division was US$15.
63 billion, accounting for 39.
9% of the business, an increase of 28.
5% compared with 12.
17 billion in 2020; the revenue of the analytical instrument division was US$6.
07 billion, accounting for 15.
5% of the business, compared with 2020.
5.
12 billion, an increase of 18.
4%; professional diagnostics revenue was US$5.
66 billion, accounting for 14.
4% of the business, an increase of 5.
9% from 5.
34 billion in 2020; laboratory products and biopharmaceutical services revenue was US$14.
86 billion, accounting for 37.
9% of the business, This is a 21.
4% increase from 12.
25 billion in 2020
.
Analytical Instruments 63 billion, accounting for 39.
9% of the business, an increase of 28.
5% compared with 12.
17 billion in 2020; the revenue of the analytical instrument division was US$6.
07 billion, accounting for 15.
5% of the business, compared with 2020.
5.
12 billion, an increase of 18.
4%; professional diagnostics revenue was US$5.
66 billion, accounting for 14.
4% of the business, an increase of 5.
9% from 5.
34 billion in 2020; laboratory products and biopharmaceutical services revenue was US$14.
86 billion, accounting for 37.
9% of the business, This is a 21.
4% increase from 12.
25 billion in 2020
.
Danaher
For the full year of 2021, Danaher's revenue was US$29.
453 billion, with a net profit of US$6.
269 billion and a profit margin of 21.
28%
.
Compared with 2020, Danaher's 2021 revenue increased by 32% and profit increased by 74%, mainly due to outstanding operations, such as cost control (cost increase of 17%), control of marketing and administrative expenses (increase of 19%) %), control of R&D expenses (increase by 29%)
.
453 billion, with a net profit of US$6.
269 billion and a profit margin of 21.
28%
.
Compared with 2020, Danaher's 2021 revenue increased by 32% and profit increased by 74%, mainly due to outstanding operations, such as cost control (cost increase of 17%), control of marketing and administrative expenses (increase of 19%) %), control of R&D expenses (increase by 29%)
.
Among the three businesses, the life sciences revenue was US$14.
958 billion, an increase of 41.
4% from US$10.
576 billion in 2020, accounting for 50.
8% of the total business; the revenue of the diagnostics business was US$9.
844 billion, an increase of 33.
0% from US$7.
403 billion in 2020 , the total business accounted for 33.
4%; the environmental and application solutions business revenue was 4.
651 billion US dollars, an increase of 8.
0% from 4.
305 billion US dollars in 2020, and the total business accounted for 15.
8%
.
958 billion, an increase of 41.
4% from US$10.
576 billion in 2020, accounting for 50.
8% of the total business; the revenue of the diagnostics business was US$9.
844 billion, an increase of 33.
0% from US$7.
403 billion in 2020 , the total business accounted for 33.
4%; the environmental and application solutions business revenue was 4.
651 billion US dollars, an increase of 8.
0% from 4.
305 billion US dollars in 2020, and the total business accounted for 15.
8%
.
Agilent
In 2021, Agilent's operating income for the full year was US$6.
32 billion, an increase of 18% year-on-year, and core business income increased by 15% year-on-year
.
32 billion, an increase of 18% year-on-year, and core business income increased by 15% year-on-year
.
Among the three groups, Life Sciences and Applied Markets Group (LSAG) had full-year revenue of $2.
82 billion, up 18% year-on-year; CrossLab Group (ACG) had full-year revenue of $2.
2 billion, up 16% year-over-year; Diagnostics and Genomics Academic Group (DGG) reported full-year revenue of $1.
3 billion, up 24% year over year
.
82 billion, up 18% year-on-year; CrossLab Group (ACG) had full-year revenue of $2.
2 billion, up 16% year-over-year; Diagnostics and Genomics Academic Group (DGG) reported full-year revenue of $1.
3 billion, up 24% year over year
.
AMETEK
For all of 2021, AMETEK's sales reached a record $5.
55 billion, up 22% from 2020
.
Operating income was $1.
31 billion and operating income margin was 23.
6%, both topping full-year results
.
55 billion, up 22% from 2020
.
Operating income was $1.
31 billion and operating income margin was 23.
6%, both topping full-year results
.
Xylem
Xylem's full-year 2021 revenue is $5.
2 billion, up 6.
5% from $4.
88 billion in 2020
.
The cost in 2021 is US$3.
22 billion, the gross profit is US$1.
975 billion, and the gross profit margin is 38%; sales and administrative expenses are US$1.
179 billion, accounting for 22.
7%, and research and development expenses are US$204 million, and research and development accounted for 3.
9%
.
2 billion, up 6.
5% from $4.
88 billion in 2020
.
The cost in 2021 is US$3.
22 billion, the gross profit is US$1.
975 billion, and the gross profit margin is 38%; sales and administrative expenses are US$1.
179 billion, accounting for 22.
7%, and research and development expenses are US$204 million, and research and development accounted for 3.
9%
.
Among the three divisions, the revenue of the water infrastructure segment was US$2.
247 billion, an increase of 8% from US$2.
079 billion in 2020; the revenue of the applied water business segment was US$1.
613 billion, an increase of 12% compared to US$1.
434 billion in 2020; measurement and control solutions Solutions segment revenue was $1.
335 billion, down 2% from $1.
363 billion in 2020
.
247 billion, an increase of 8% from US$2.
079 billion in 2020; the revenue of the applied water business segment was US$1.
613 billion, an increase of 12% compared to US$1.
434 billion in 2020; measurement and control solutions Solutions segment revenue was $1.
335 billion, down 2% from $1.
363 billion in 2020
.
Perkin Elmer
For the full year of 2021, PerkinElmer's turnover reached US$5.
067 billion, an increase of 34% compared with US$3.
783 billion in the same period last year, and also exceeded previous industry expectations.
This is the second time in a row that PerkinElmer has achieved over 30%.
growth
.
067 billion, an increase of 34% compared with US$3.
783 billion in the same period last year, and also exceeded previous industry expectations.
This is the second time in a row that PerkinElmer has achieved over 30%.
growth
.
DAS segment sales increased 24% to $2.
135 billion from $1.
716 billion in 2020, while Diagnostics segment sales increased 42% from $2.
067 billion to $2.
932 billion
.
PerkinElmer's total COVID-19-related revenue for the year was approximately $1.
6 billion
.
135 billion from $1.
716 billion in 2020, while Diagnostics segment sales increased 42% from $2.
067 billion to $2.
932 billion
.
PerkinElmer's total COVID-19-related revenue for the year was approximately $1.
6 billion
.
Illumina
Illumina's operating income for 2021 was $4.
526 billion, up 40% from $3.
239 billion in fiscal 2020
.
526 billion, up 40% from $3.
239 billion in fiscal 2020
.
Illumina's 2021 R&D expenses nearly doubled to $1.
19 billion from $682 million in 2020
.
In addition, the company's SG&A expense in 2021 also more than doubled from $941 million in 2020 to $2.
09 billion
.
19 billion from $682 million in 2020
.
In addition, the company's SG&A expense in 2021 also more than doubled from $941 million in 2020 to $2.
09 billion
.
METTLER TOLEDO
On a GAAP basis, the company's earnings per share in 2021 were $32.
78, compared to $24.
91 a year earlier
.
Compared with the prior year, total reported sales rose 21% to $3.
718 billion
.
By region, Americas reported a 20% increase in sales, Europe was up 15%, and Asia/RW was up 26%
.
Profit before tax was $949.
4 million, compared to $748.
7 million in the prior year
.
78, compared to $24.
91 a year earlier
.
Compared with the prior year, total reported sales rose 21% to $3.
718 billion
.
By region, Americas reported a 20% increase in sales, Europe was up 15%, and Asia/RW was up 26%
.
Profit before tax was $949.
4 million, compared to $748.
7 million in the prior year
.
Bio-Rad
Bio-Rad's full-year 2021 net sales were $2,922.
5 million, an increase of 14.
8% from $2,545.
6 million in fiscal 2020
.
On a currency-neutral basis, net sales rose 12.
7%
.
5 million, an increase of 14.
8% from $2,545.
6 million in fiscal 2020
.
On a currency-neutral basis, net sales rose 12.
7%
.
Among the two segments, the Life Sciences segment reported full-year net sales of $1,400.
8 million, an increase of 13.
7% compared to 2020; and the Clinical Diagnostics segment reported full-year net sales of $1,515.
9 million, compared to 2020 an increase of 16.
1%
.
8 million, an increase of 13.
7% compared to 2020; and the Clinical Diagnostics segment reported full-year net sales of $1,515.
9 million, compared to 2020 an increase of 16.
1%
.
Waters
Waters' total sales in 2021 were $2,786 million, an increase of 18% year-over-year and 16% in constant currency, compared to $2,365 million in 2020
.
.
In fiscal 2021, Waters pharmaceutical market sales were up 20% as reported, industrial market sales were up 17% as reported, and academic and government market sales were up 7%
.
.
Regionally, sales in Asia were up 20% as reported, 19% in constant currency, 16% in the Americas (14% in the U.
S.
), and 17% in Europe, up 17% in constant currency Compute grew 14%
.
S.
), and 17% in Europe, up 17% in constant currency Compute grew 14%
.
Brooke
Brooke's fiscal 2021 revenue was $2,417.
9 million, an increase of 21.
7% from $1,987.
5 million in fiscal 2020
.
9 million, an increase of 21.
7% from $1,987.
5 million in fiscal 2020
.
By business segment, Bruker Scientific Instruments (BSI) revenue for fiscal 2021 was $2,208.
1 million, an increase of 22.
0% compared to 2020, of which organic growth was 19.
4%
.
Bruker Energy and Superconducting Technologies (BEST) revenue was $223.
8 million, an increase of 18.
1%
.
Organic growth at BEST, net of intercompany offsets, was 15.
5%
.
1 million, an increase of 22.
0% compared to 2020, of which organic growth was 19.
4%
.
Bruker Energy and Superconducting Technologies (BEST) revenue was $223.
8 million, an increase of 18.
1%
.
Organic growth at BEST, net of intercompany offsets, was 15.
5%
.
Qiagen
The report shows that net sales for the full year of 2021 will increase from $1.
87 billion in the previous year to $2.
252 billion, a year-on-year increase of 20%
.
87 billion in the previous year to $2.
252 billion, a year-on-year increase of 20%
.
In terms of product types, Qiagen's consumer goods and related revenue in 2021 will be US$1.
986 billion, a year-on-year increase of 23%; instrument revenue will be US$265 million, a year-on-year increase of 4%; molecular diagnostic revenue will be US$1.
144 billion, a year-on-year increase of 27%; life Science-related revenue was $1.
108 billion, up 15% year over year
.
986 billion, a year-on-year increase of 23%; instrument revenue will be US$265 million, a year-on-year increase of 4%; molecular diagnostic revenue will be US$1.
144 billion, a year-on-year increase of 27%; life Science-related revenue was $1.
108 billion, up 15% year over year
.
Original title: Summary analysis of the 2021 performance of 12 multinational instrument companies with the highest growth exceeding US$7.
1 billion
1 billion
